Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II clinical trial of navicixizumab in patients with ovarian cancer (including peritoneal or fallopian tube cancer) who have become resistant to their prior therapies

Next Previous
Trial Profile

A phase II clinical trial of navicixizumab in patients with ovarian cancer (including peritoneal or fallopian tube cancer) who have become resistant to their prior therapies

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Navicixizumab (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Mereo BioPharma

Most Recent Events

  • 17 Jul 2019 New trial record
  • 15 Jul 2019 According to a Mereo BioPharma media release, in the Type B meeting with FDA the company has discussed and agreed in principle, an outline for the design of the trial. This trial could potentially support the accelerated approval of navicixizumab in patients with ovarian cancer (including peritoneal or fallopian tube cancer) who have become resistant to their prior therapies.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top